Acute Promyelocytic Leukemia in Children: a Report on Eleven Cases

Area of Science:

• Hematology
• Pediatric Oncology
• Leukemia Research

Background:

• Acute promyelocytic leukemia (APL) is a rare subtype of leukemia.
• Pediatric APL cases constitute a significant portion of APL patient populations in some centers.
• Understanding APL in children is crucial for developing effective treatment strategies.

Purpose of the Study:

• To analyze the clinical characteristics and treatment outcomes of pediatric patients with acute promyelocytic leukemia (APL).
• To compare the disease-free survival (DFS) of pediatric APL patients with adult APL patients.
• To explore potential therapeutic reinforcements for improving outcomes in pediatric APL.

Main Methods:

• Retrospective analysis of 11 pediatric patients diagnosed with APL.
• Review of cytological features, genetic translocations (15;17), and clinical presentation including disseminated intravascular coagulation (DIC).
• Evaluation of induction chemotherapy regimens (daunorubicin, Ara-C, zorubicin) and outcomes including complete remission (CR), relapse, and survival.

Main Results:

• Seven out of 11 pediatric patients (64%) achieved complete remission (CR).
• Disease-free survival (DFS) in pediatric patients was significantly shorter compared to adult APL patients treated with similar regimens.
• Relapse occurred in 5 out of 7 complete remitters within 3 to 13 months, with a median survival of 5.5 months.

Conclusions:

• Pediatric acute promyelocytic leukemia (APL) is associated with shorter remission durations and poorer survival compared to adult APL.
• The findings suggest a need for intensified consolidation therapy, such as allogeneic bone marrow transplantation, in pediatric APL patients post-CR.
• Further research into novel therapeutic strategies is warranted for improving long-term outcomes in children with APL.